StemCell Therapy

The first UK frontline NHS worker will today enrol in a new study designed to test the potential of hydroxychloroquine to prevent infection with novel coronavirus.

COPCOV is the largest multi-national interventional clinical study into the prevention of COVID-19 using hydroxychloroquine, which will involve around 40,000 healthcare workers.

The study has launched at Brighton and Sussex University Hospitals and the John Radcliffe Hospital in Oxford, which are the first of 20 UK hospitals set to participate.

Researchers hope to determine whether hydroxychloroquine/chloroquine can be used to effectively protect frontline medical staff, allowing them to undertake their vital roles more safely.

Accord Healthcare, a UK-based medicines manufacturer, has donated over two million tablets to enable this landmark trial to go ahead.

Based on the known pharmacology of hydroxychloroquine, coupled with the emerging knowledge surrounding SARS-CoV-2 viral replication and COVID-19 pathophysiology, we were very keen to test the effectiveness of this molecule in a preventative, rather than late-stage treatment setting, said Dr Anthony Grosso, VP & head of Scientific Affairs, Accord Europe & MENA.

A large-scale, prospective, randomised, double-blind clinical trial in a high-risk setting is the only way to robustly determine if this medicine can lessen or prevent human infection. Previous studies have not adequately tested this hypothesis; the results of COPCOV are therefore of critical importance to public health.

Even though lock-down measures appear to have significantly reduced the current rate of infection in the UK, healthcare workers will continue to be at risk of contracting COVID-19, especially as measures are relaxed, added Professor Martin Llewelyn, Brighton and Sussex Medical School and lead COPCOV UK Investigator.

Whilst we wait for an effective and widely available vaccine, the race is on to find a well-tolerated preventative treatment. The results from COPCOV are expected later this year and, if they show that hydroxychloroquine can reduce the chances of catching COVID-19, this would be incredibly reassuring for myself and my frontline colleagues.

Read the original here:
First UK healthcare worker to enrol in COVID-19 prevention trial - PharmaTimes

The buck arguably stops with Dr. Wilma Wooten as the San Diego region starts to reopen its economy amid the worst pandemic in a century.

Wooten, the countys public health officer, cleared the way this week for resuming in-person dining at restaurants, as well as shopping at retail stores and swap meets. Her plan, which received state approval on Wednesday, makes San Diego the largest county in California to move ahead on Gov. Gavin Newsoms official timeline for easing lockdown conditions.

So far, the region has fared notably well under Wootens leadership when it comes to fending off the new coronavirus. Hospitals have not been overwhelmed with sick patients, and while its taken time, testing capacity and contact tracing appear to be ramping up.

Still, the largest challenge for the 63-year-old Alabama native may lie ahead. As corporate heavyweights and small business owners push for commerce to resume, health experts have said hospitals should brace for a spike in illnesses and deaths.

Wooten is a widely respected medical professional who received high praise for her handling of the 2009 swine flu outbreak that started in San Diego, but her political skills could be tested. Four years ago, she was thrust into the spotlight when a rash of hepatitis A cases ripped through the local homeless community. A state audit found she mishandled the crisis by not forcing the city to deal with the outbreak sooner and more forcefully.

A spate of new COVID-19 cases could force Wooten into a faceoff with elected leaders eager to please their out-of-work constituents something she says shes prepared for.

It will be difficult to dial back, but we will have to if things get out of hand, she said during an interview Thursday. This is a challenge of all health officers across the nation.

So far, disagreements over tackling the coronavirus pandemic have been relatively minor, such as when conservative Supervisor Jim Desmond recently downplayed the seriousness of the coronavirus outbreak by pointing out that all but six of the countys fatalities involved underlying health conditions.

Dr. Wilma Wooten, San Diego County public health officer

Wooten quickly rebutted the supervisors comments at one of the countys regular press briefings, saying that the lives of those with existing medical conditions were no less valuable than others.

Still, Desmond is not alone in his push to loosen restrictions far beyond what Newsom and his team in Sacramento have called for. San Diego Mayor Kevin Faulconer and the entire Board of Supervisors save its lone progressive, Supervisor Nathan Fletcher have called for reopening the economy far beyond what the state and the health officer appear comfortable with.

Wooten, with Fletchers support, has repeatedly called for following the guidance of state leaders as well as the Centers for Disease Control and Prevention.

We are very sensitive of the importance to balance protection of the publics health with economic viability, and we are following the governors guidance, she said.

That message comes in contrast to a letter recently penned by San Diego Mayor Kevin Faulconer and Supervisor Greg Cox urging the governor to allow local jurisdictions to control the speed at which they reopen.

Our businesses are ready to thoughtfully reopen and adapt with necessary protective measure, but they need to be provided that opportunity, the letter reads in part.

Wooten grew up with what she described as meager means in Thomaston, Ala., a rural town of fewer than 1,000 people and one streetlight.

Raised by her great grandparents, she and her brother spent a lot of time helping the local elderly community. She said the experience helped her develop an enduring sense of public service, and from a young age, she knew she wanted to get into medicine.

Valedictorian of her high school class, she attended Spelman College in Atlanta. Before graduating from the historical black college for women in 1978, she met Roslyn Crisp, who would become her lifelong friend.

Crisp, a 63-year-old pediatric dentist from North Carolina, said they mostly avoided parties and focused on their academic careers. They still see each other a few times a year and regularly vacation together.

She has the qualities that I think anybody would want in a friend, Crisp said of Wooten. Shes very compassionate. Shes understanding. Shes a good listener.

If she gives you an opinion, honestly, I really feel like she has thought it out, and shes done her homework.

Wooten went on to attended the University of North Carolina School of Medicine, where she graduated with a degree in medicine in 1986. She did her residency at the recently closed Providence Hospital in Washington, D.C.

She came to San Diego in 1989 to do her residency in preventative medicine at San Diego State University under Dr. Kevin Patrick, now a professor emeritus of family medicine and public health at the UC San Diego School of Medicine.

A year later on Patricks advice, Wooten applied to work at UCSD and was hired to, among other things, research family and preventive medicine.

She was very practical in her approach to things and very hard working, Patrick recalls. Obviously, she cares for the community. I think the social justice component was really important for Wilma.

Wooten was hired by San Diego County in 2001 to serve as deputy health officer. At the time, she was also volunteering on medical trips to Jamaica, Kenya and Ghana to treat and educate patients vulnerable to communicable diseases, such as AIDS.

In 2007, she was elevated to public health officer, overseeing the countys Public Health Services agency, which currently has about 500 employees and a $100 million budget. She currently makes a salary of $270,836 a year.

Her first big challenge came in 2009, when San Diego became ground zero for the countrys H1N1 swine-flu epidemic. Wooten would later win a national Public Health Heroes award for her work.

She is one of my public-health heroes, said Dr. Ron Chapman, public health officer for Californias Yolo County. He serves with her on the Public Health Accreditation Board. Dr. Wooten is brilliant, insightful, caring, and a strategic thinker.

Dr. Wilma Wooten showed the proper way to cough during a 2009 briefing on the H1N1 flu death of a county resident.

In March 2017, Wooten declared an outbreak of hepatitis A, which was infecting homeless people and illegal drug users through feces. Nobody knew at the time, but it would become the countrys worst eruption of the disease since a vaccine was introduced in 1995.

What happened over the next six months led to intense media scrutiny and finger pointing between county officials and San Diego Mayor Kevin Faulconers team.

While the county would later suggest the city dragged its feet on sanitation, the mayors team faulted the county for not taking charge during the outbreak.

This is a dark stain on our communitys civic record, said Assemblyman Todd Gloria, D-San Diego. Hepatitis is a disease that we know a lot about, that we have tests for, that we have a vaccine for. The fact that it killed 20 people and infected over 500 more was a real indictment of our public health infrastructure.

At the time, the city much like other parts of Southern California that experienced simultaneous, albeit smaller outbreaks of hepatitis A had long been entwined in a debate about whether homeless communities had adequate access to toilets and proper sanitation.

Advocates had routinely criticized Faulconer for not increasing the number of public toilets downtown, citing grand jury reports from 2010 and 2015 that warned unsanitary conditions in the city could lead to an outbreak of disease.

The issue became a political hot potato, with residents and local business owners complaining that public toilets invited unsavory behavior. In 2015, the mayor removed one of two metal toilets downtown, known as Portland Loos, which had cost the city roughly $560,000. The second loo was then removed at the height of the hepatitis outbreak.

Assemblyman Todd Gloria, D-San Diego

Wooten issued the first public health directive of her career on Aug. 31, 2017, calling on the city of San Diego to expand access to public restrooms and hand-washing stations, as well as to ramp up street-cleaning efforts.

The next day she declared a health emergency, and Faulconer made his first public statements on the issue, despite that fact that the city had quietly warned its own workers for months about the danger of infection.

Nobody wanted to take the lead, recalled Michael McConnell, a prominent local advocate for the homeless. Nobody wanted to be in charge of this thing, and on the ground it was just a train wreck.

Wooten and her team ramped up a vaccination program that eventually helped stem the outbreak.

However, California State Auditor Elaine Howle released a report in 2018 that found they should have acted faster. It faulted both the city and the county for not tackling sanitation earlier, but called out the county for being too lenient with Faulconers team.

The county health officer did not issue a directive sooner because she wanted to collaborate with the city instead of mandating its compliance, the report read. However, by exercising her legal authority before August 31, 2017, the county health officer likely would have prompted the city to implement the important sanitation measures sooner.

Gloria and Assemblywoman Lorena Gonzalez, D-San Diego, co-authored a bill in response to the audit report that cemented a local health officers authority to compel other government agencies to take action to curb the spread of disease.

According to the audit report, the countys own legal counsel questioned Wootens authority to issue Faulconer the health directive.

Neither Wooten nor Faulconer want to relitigate the hepatitis A crisis, citing the need to collaborate during the current pandemic.

That happened, and were in a different place now, and we have a great relationship with actually all of the municipalities that are in San Diego County, Wooten said.

Wooten has been much more visible in the current crisis, and the stakes are much higher due to the weeks-long shutdown of the economy and pressure to reopen it. She and other officials are giving regular video updates on Facebook and Twitter concerning issues that intimately impact the lives of nearly everyone in the county, from wearing face masks to opening local beaches.

The relationships been a bit rocky at times.

Wooten, for example, suggested in a press briefing this month that she would block casinos on tribal lands from reopening, saying: We feel that the health officers order does extend to our tribal nations in this particular situation.

Wooten reversed her position the next day after meetings with tribal leaders, acknowledging that, Tribal nations have sovereign authority, so our plan is to provide guidance and advice where possible.

In an appearance at the Rock Church on March 15, Wooten dismissed the idea that the virus could be spread by those without symptoms.

Oh, I heard that it was that you could without symptoms, said Pastor Miles McPherson during an exchange.

There are a lot of rumors and misinformation out there, Wooten responded. Even if theyve been exposed to someone who did have symptoms, if they do not have symptoms, others who have come in contact with that individual should be at low or no risk for developing the disease.

At the time, evidence of asymptomatic transmission was just starting to percolate. Its now believed that has played a significant role in spreading the virus. Wooten was not technically wrong about the state of research at the time, as shes quick to point out.

That was not a misstep, Wooten told the Union-Tribune. That was based on the facts that we had that day.

County public health officer Wilma Wooten M.D., and other officials, provide the latest updates on COVID-19 Coronavirus at the County Operations Center on February 14, 2020 in San Diego, California.

(Eduardo Contreras/The San Diego Union-Tribune)

Now Wooten has taken another bold leap into the unknown.

On Tuesday, she submitted a plan to the state for reopening restaurants, retail businesses and swap meets. Officials in Sacramento approved the plan the next day, making San Diego a test case for lifting stay-at-home orders in a highly urbanized area.

While Los Angeles County doesnt currently appear to meet the states requirements for reopening such businesses, several Bay Area counties seemingly do but have chosen to remain under lockdown, including Marin, San Mateo, Contra Costa, Sonoma and San Francisco.

San Diego has fared reasonably well during the pandemic, with about 6,300 cases and about 240 deaths as of Friday. Still, the decision to reopen comes at a time when the region is barely meeting the states benchmarks for doing so.

For example, the state has required as a condition for reopening such businesses that San Diego County be testing at least 4,950 people for the virus a day, or 1.5 people per 1,000 residents. The county reports that its currently testing only about 4,000 people a day on average, although it expects to meet or exceed the states benchmark by June.

The state has also called for counties to have enough open hospital beds to accommodate a surge in COVID-19 patients of roughly 35 percent. San Diego County currently has just enough free space across its 24 hospitals to meet the requirement, according to the report.

Theres also a question about whether the San Diego has enough contact tracers to be able to isolate infection clusters before they get out of control.

The state has called on counties to have at least 15 contact tracers for every 100,000 residents in order to open shops and eateries. That would be roughly 500 trained professionals for the San Diego region. Currently, the county reports that it has only 87 tracers, although its says the county has hired another 329 tracers that are currently completing their training. San Diego State University will also provide another 100 tracers at some point, according to the county.

Still, Wootens plan for reopening certain businesses appears to have the support of the local medical community. UC San Diego Health CEO Patty Maysent called the plan on Tuesday incredibly thoughtful.

I think it addresses the main issues that we need to follow, she said. The metrics that are laid out in the plan are in my mind pretty factually based.

The plan also has the backing of Fletcher, who appears to be Wootens firewall against politicians who would swing the doors open on the economy tomorrow if they could.

Dr. Wooten is one of the hardest-working public servants that Ive encountered in my time working in government, he said. She works on these issues of public health every single day, seven days a week, all day long.

Read more here:
Meet Dr. Wilma Wooten, who wrote the plan to open San Diego restaurants and shops - The San Diego Union-Tribune

Naoki Yuda,1 Miyuki Tanaka,1 Koji Yamauchi,1 Fumiaki Abe,1 Izumi Kakiuchi,2 Kyoko Kiyosawa,2 Mitsunaga Miyasaka,2 Naoki Sakane,3 Masahiko Nakamura4

1Food Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa, Japan; 2Department of Nursing, Matsumoto Junior College, Matsumoto, Nagano, Japan; 3Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; 4Matsumoto City Hospital, Matsumoto, Nagano, Japan

Correspondence: Naoki YudaFood Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome, Higashihara, Zama, Kanagawa, JapanTel +81 46 252 3051Fax +81 46 252 3017Email n-yuda@morinagamilk.co.jp

Background: Preventative measures have recently been taken to reduce the incidence of Alzheimers disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the bloodbrain barrier, attenuated cognitive decline in a mouse model of Alzheimers disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia.Methods: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 g MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety.Results: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed.Conclusion: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function.

Keywords: humans, MKP, cognition, cognitive dysfunction, orientation, Alzheimers disease

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function | CIA - Dove Medical Press

Text Size:A- A+

New Delhi: The Indian Council of Medical Research (ICMR), the countrys apex body in the field, has found that consuming the drug hydroxychloroquine reduces the chances of getting infected with Covid-19.

As a result, ICMR released an advisory Friday to expand the usage of HCQ an anti-malarial drug as a preventive treatment against the novel coronavirus.

The conclusion has been drawn on the basis of three studies conducted by the ICMR.

The advisory suggests surveillance workers, paramilitary and police personnel, as well as medical staff working in non-Covid hospitals and blocks to start consuming the pill as preventive therapy.

ICMR had issued an advisory to begin using HCQ in March, but it had drawn criticism for lacking scientific evidence that the drug works against the novel coronavirus.

Also read: How the humble hydroxychloroquine has become Indias unlikely new global strategic asset

According to the advisory, the premier health body undertook investigation at three central government hospitals in New Delhi. While it did not reveal the names of the hospitals, it said the investigation indicates that amongst healthcare workers involved in Covid-19 care, those on HCQ prophylaxis were less likely to develop SARS-CoV-2 infection, compared to those who were not on it.

The advisory also states that the National Institute of Virology in Pune has found in laboratory testing that HCQ reduces the viral load.

The ICMR also analysed data collected previously, known as retrospective case-control analysis, and found a significant relationship between the number of doses taken and frequency of occurrence of Covid-19 infection in symptomatic healthcare workers who were tested for SARS-CoV-2 infection.

It further said the benefit was less pronounced in healthcare workers caring for a general patient population.

Another observational study was conducted among 334 healthcare workers at the countrys largest public hospital, New Delhis All India Institute of Medical Sciences (AIIMS). The 248 workers who took HCQ as preventive drug for an average of six weeks had lower incidence of the infection than those not taking the pill.

Based on the findings of the studies, the government has decided to administer the drug as a prophylaxis or preventive therapy to asymptomatic healthcare workers working in non-Covid hospitals as well as non-Covid blocks of hospitals earmarked for Covid treatment.

Asymptomatic frontline workers, such as surveillance workers deployed in containment zones, as well as paramilitary and police personnel involved in Covid-related activities will be asked to pop HCQ pills.

Until now, only high-risk individuals, including asymptomatic healthcare workers involved in containment and treatment of Covid-19 patients, and asymptomatic household contacts of laboratory-confirmed cases, were being administered the drug. They will continue to consume the drug.

While the dosage will remain the same as before, eight weeks, the ICMR advisory suggests that it can be used beyond that period as well, but with close monitoring.

With available evidence for its safety and beneficial effect as a prophylactic drug against SARS-CoV-2 during the earlier recommended 8 weeks period, the experts further recommended for its use beyond 8 weeks on weekly dosage with strict monitoring of clinical and ECG parameters, which would also ensure that the therapy is given under supervision, it stated.

In clinical practice, HCQ is commonly prescribed in a daily dose of 200mg to 400mg for treatment of diseases such as rheumatoid arthritis and systemic lupus erythematosus for prolonged treatment periods with good tolerance, the advisory added.

The ICMR had earlier announced that some side effects, such as abdominal pain and nausea, have been observed in healthcare workers who were administered HCQ.

The anti-malaria drug isoften blamed for triggering irregular heartbeat.

However, in the final results of the studies (HCQ prophylaxis among 1,323 healthcare workers), the ICMR found mild adverse effects such as nausea in 8.9 per cent workers, abdominal pain in 7.3 per cent, vomiting in 1.5 per cent, low blood sugar (hypoglycaemia) in 1.7 per cent and cardio-vascular effects in 1.9 per cent.

The advisory states the drug should be discontinued if it causes the rare side effects related to the heart, such as cardiomyopathy, a disease which makes it harder for heart to pump blood to the entire body, and heart-rate disorders.

The advisory mentions that HCQ, in rare cases, can cause visual disturbance, including blurring of vision, which is usually self-limiting and improves on discontinuation of the drug.

ICMR has clarified that for the above cited reasons heart and vision the drug has to be given under strict medical supervision with an informed consent.

Also Read: Ashwagandha the new HCQ? Modi govt begins study to see if herb keeps coronavirus away

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Original post:
HCQ breakthrough: ICMR finds its effective in preventing coronavirus, expands its use - ThePrint

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1702.89 mn during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The presence of a large patient pool has been instrumental in driving the growth of the market.

Neuropathy Pain Treatment Market 2020-2024 : Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024 : Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our neuropathy pain treatment market report covers the following areas:

This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Neuropathy Pain Treatment Market 2020-2024 : Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the neuropathy pain treatment market, including some of the vendors such as Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi Backed with competitive intelligence and benchmarking, our research reports on the neuropathy pain treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024 : Key Highlights

Table Of Contents :

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by Drug Class

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read this article:
Research Report with COVID-19 Forecasts - Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio -...

The Global Diabetic Neuropathy Market 2020 Research Report is a professional and in-depth study on the current state of Diabetic Neuropathy Market.

This is the latest report, covering the current COVID-19 impact on theDiabetic Neuropathy market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides the latest insights about the Diabetic Neuropathy market drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

Click here to get the short-term and long-term impact of COVID-19 on this Market:https://marketresearch.biz/report/diabetic-neuropathy-market/covid-19-impact

The Diabetic Neuropathy Market Report Covers the Following Companies:

Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants to understand the competitive scenario to plan future strategies.

For Better Understanding, Download FREE Sample PDF Copy of Diabetic Neuropathy Market Research Report :https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

The Report Provides:

An overview of the Diabetic Neuropathy market

Current COVID-19 impact on the Diabetic Neuropathy market

Comprehensive analysis of the market

Analyses of recent developments in the market

Events in the market scenario in the past few years

Emerging market segments and regional markets

Segmentations up to the second and/or third level

Historical, current, and estimated market size in terms of value and volume

Competitive analysis, with company overview, products, revenue, and strategies.

An impartial assessment of the market

Strategic recommendations to help companies increase their market presence

Download FREE Sample PDF Copy Now!

The Diabetic Neuropathy Market Report Addresses the Following Queries:

What is the estimated size of the market by 2029?

Which segment accounted or a large share of the market in the past?

Which segment is expected to account the largest market share by 2029?

Which governing bodies have approved the use of Diabetic Neuropathy?

Which region accounts for a dominant share of the market?

Which region is anticipated to create lucrative opportunities in the market?

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

Europe (Germany, the UK, France, and Rest of Europe)

North America (the US, Mexico, and Canada)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (GCC Countries and Rest of the Middle East & Africa)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Read the original here:
Diabetic Neuropathy Market All-Inclusive Research Report 2020 : Includes Impact of COVID-19 On Market - Cole of Duty

Newswise BOSTON - Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

The American Association for Cancer Research (AACR) announced that in partnership with the Lung Cancer Initiative at Johnson & Johnson (LCI) it will award $1 million dollars to a multi-institutional team focused on developing digital tools to engage high-risk smokers in an innovative smoking cessation program designed to encourage behaviors that promote lung health.

This team project is co-led by Dana-Farber nurse-scientist Mary E. Cooley, PhD, RN, FAAN, whose research arose out of her experience as an advanced practice nurse working as part of a multidisciplinary team focused on treating and supporting lung cancer patients and their families. Smoking cessation, even after the diagnosis of lung cancer, is essential to improving clinical outcomes, said Cooley. Our hope is this program encourages behaviors that promote lung health and early lung cancer detection. The other co-leaders are Peter Castaldi, MD, MSC, assistant professor of medicine at Harvard Medical School and Sun S. Kim, PhD, associate professor of nursing at the University of Massachusetts.

A separate research project recently received funding from the National Institutes of Health (NIH) to study chemotherapy-induced peripheral neuropathy. The study, led by Dana-Farber nurse-scientist Robert Knoerl, PhD, RN, looks at metabolomic and genetic markers of neuropathy in adolescents and young adults with cancer.

Essentially theres only one first-line treatment for neuropathy, said Knoerl. One reason for the lack of effective treatments is that we dont understand the underlying causes of neuropathy. We hope with this study to identify potential biomarkers that can be targeted in the future.

The mission of the Cantor Center is to reduce the burden of cancer through scholarly inquiry and rigorous research. The focus of the Centers research is the patient/family experience of living with cancer, as well as survivorship issues post-treatment.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the worlds leading centers of cancer research and treatment. It is ranked in the top 5 of U.S. News and World Reports Best Hospitals for both adult and pediatric cancer care. Dana-Farbers mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Go here to read the rest:
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants - Newswise

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

After every treatment at Women & Infants Hospital in Providence, Rhode Island, the 15-year survivor of ovarian cancer adds sparkling creations to an earring tree placed there by volunteers. Patients are free to choose from and keep the jewelry that hangs there.

Dziobek also gives away jewelry when shes treated at Dana-Farber Cancer Institute in Boston. She has made rings for patients whose swollen fingers are too large for standard sizes and instructed others in bracelet-making techniques.

It makes people feel good and doing something productive while Im here gives me purpose, Dziobek, a retired nurse, says. A couple of months ago, a woman told me that my blue earrings were the only ones she could find that matched her dress for her daughters wedding. She was in the middle of her treatment and had no hair, but she had a beautiful scarf with the earrings to match her dress. It really helped, and she couldnt thank me enough. I had tears in my eyes; it was like a connection was made. You dont realize the impact you have when you do something like this.

Dziobek picked up her hobby in 2010 and was taking classes at a bead store when she experienced a recurrence of her cancer, first diagnosed in 2004. After radiation, she joined a clinical trial of intraperitoneal chemotherapy plus the targeted drug Velcade (bortezomib), but complications arose after one treatment, and she needed surgery. That was followed by six months of intravenous chemotherapy.

While recovering, Dziobek periodically reflected on a cuff bracelet shed begun before treatment. Although she was not sure if she would be able to follow the directions or do the intricate beading work due to her brain fog and neuropathy, she returned to her project. It took her three months to finish.

It helped me to focus, and I started to come out of the fog of chemo brain and my hands felt better, she recalls.

I felt like I was creating new pathways in my brain by focusing and figuring out color palette, placement of beads and measurements.

Dziobek was still part of the beading group, and her fellow members decided to help other patients enjoy a similar experience. They developed the Plum Blossom Project, bringing beaders to cancer centers to instruct patients in making bracelets. After completing a piece, each patient was gifted a beaded necklace made by volunteers. Dziobeks husband, Joe, helped raise funds for the project by selling CDs of two songs he wrote and performed, one about Plum Blossom and the other about the caregivers journey (youtube. com/watch?v=cd3DotLtwrE).

The group recently stopped working with patients who have cancer, but a few years ago Dziobek invited members to give a class for the gynecologic cancers support group at Women & Infants, where she goes twice a week for magnesium infusions to treat a long-term side effect of chemotherapy.

It made a difference for participants, especially one woman and her daughter.

The mom, who had been in treatment all day, wanted to take the class, but the daughter was burnt out and wanted to get home, Dziobek recalls. In the 15 to 20 minutes that they were selecting beads and putting their bracelets together, we could see the daughters shoulders and facial muscles relax, and the conversation changed. By the time they left, rather than a stressed-out caregiver taking care of a relative, it was now a mother-daughter relationship. They were excited about the bracelets theyd made, and their whole demeanor changed.Their story is a reminder, Dziobek says, of the importance of finding something enjoyable to do during cancer treatment, an idea she keeps front of mind as she prepares to enter a clinical trial at Dana-Farber.

Treatment really wears you down and the toll is cumulative, but if theres something you can do to help yourself at least feel a little better, do it, suggests Dziobek, who also finds meaning by volunteering with the Partnership to Reduce Cancer in Rhode Island, a community advisory group that works with the state health departments comprehensive cancer control program.

The partnership holds an annual June cancer summit, for which Dziobek is planning a survivor-led presentation to show participants how to make meditation bracelets and emphasize the health benefits of beading.

I firmly believe that we have to have some purpose each day and something to look forward to, no matter how we feel, she says. It continues to give you hope and keeps you moving forward.

See the original post:
Finding Meaning While Waiting in the Infusion Chair - Curetoday.com

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

- Data continue to support a NaPi2b biomarker-based patient selection strategy

- Generally well-tolerated with no new safety signals

- Data to be presented on a conference call today at 8 a.m. ET and at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma.The Company will host a conference call and webcast today,Wednesday, May 27, 2020, at8:00 a.m. ETduring which investigatorDebra L. Richardson, MD, Associate Professor of Gynecologic Oncology at theStephenson Cancer Centerat theUniversity of Oklahoma Health Sciences Centerand theSarah Cannon Research Instituteand members of the Mersana executive team will present and discuss these data. These data will also be presented in a poster session at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020 starting at 8:00 a.m. ET.

These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. XMT-1536 continues to demonstrate that it is generally well tolerated, without the dose-limiting toxicities of other ADC platforms such as severe neutropenia, neuropathy and ocular toxicity. These are encouraging signals as we look forward to reporting more mature data in the second half of the year and continuing to advance XMT-1536 for both platinum-resistant ovarian cancer and NSCLC adenocarcinoma patients.

The expansion portion of the Phase 1 study is enrolling patients with platinum-resistant ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy and in some cases four lines of prior therapy regardless of platinum status as well as patients with NSCLC adenocarcinoma who had received prior treatment with platinum-based therapy and immunotherapy or targeted agents. With a data cutoff of May 1, 2020 these data include 34 patients total, 27 with ovarian cancer and seven with NSCLC adenocarcinoma. Patients with ovarian cancer had a median of three prior lines of treatment (range 1-5), and patients with NSCLC adenocarcinoma had a median of two lines of therapy (range 1-3).Fifteen of the patients were dosed at 36 mg/m2, and 19 patients were dosed at 43 mg/m2 every four weeks. Key findings include:

*7 patients not evaluable: 1 withdrew consent (Lower NaPi2b Expression); 1 with unrelated SAE leading to discontinuation and death (Lower NaPi2b Expression); 5 have not yet received a scan**uPR=1 patient with unconfirmed PR; confirmatory scan pending at the time of data cutHigher NaPi2b Expression: defined in dose escalation as at / above lowest H-score at which response observed (110)Lower NaPi2b Expression: defined in dose escalation as below the lowest H-score at which response observed (<110)

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the Mersana executive team will present and discuss these data. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7785868. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials and expectations regarding future clinical results based on data achieved to date. Forward-looking statements generally can be identified by terms such as aims, anticipates, believes, contemplates, continues, could, estimates, expects, goal, intends, may, on track, plans, possible, potential, predicts, projects, seeks, should, target, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later clinical trials, and that the development and testing of the Companys product candidates will take longer and/or cost more than planned, as well as those listed in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020, the Companys Quarterly Report on Form 10-Q filed with the SEC on May 8, 2020 and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Companys preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Companys operations and the value of and market for the Companys common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contact:

Investor & Media ContactSarah Carmody617-844-8577scarmody@mersana.com

Here is the original post:
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study - GlobeNewswire

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

What the report encloses for the readers:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Liquid Chromatographymass Spectroscopy MarketLiquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic Testing.For More Information

Biopharmaceutical MarketBiopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
Neuropathic Pain Market to Witness CAGR 5.6% Growth in Revenue During the Period 2024 - WaterCloud News

THE WOODLANDS, TX - A number of Houstons aging residents are turning to non-invasive regenerative therapies to get relief from chronic pain associated with degenerative conditions like osteoarthritis, neuropathy, back and joint pain.

Doctors Jeffery Pruski, D.C., and Edward Nash, M.D., are pain management and regenerative medicine specialists at 3R Regenerative Repair & Relief (3R), located just outside of Houston in The Woodlands, Texas. Over the past three years, the doctors have seen a steady rise in patients over the age of 55 looking for alternatives to knee replacements, back surgeries, and opioid pain medications to relieve chronic pain.

As we age, the body loses its natural ability to heal itself, said Dr. Pruski. Unlike traditional pain management, which typically treats the symptoms of the pain with surgery or medications, regenerative therapies treat the root cause of the pain. It creates a healing environment inside the joint, or area of degeneration, that uses the bodys own healing capacity to regenerate healthy cells and restore normal function to damaged areas.

Older adults are more likely to experience chronic pain conditions like osteoarthritis, cancer, neuropathies and osteoporotic-related fractures.

Dr. Pruski believes more seniors are choosing regenerative therapies over traditional treatments out of concerns with taking opioid medications and because, compared to surgery, there is no trauma to the body, no anesthesia, no cutting of the skin or foreign implants; all of which pose additional health risks to one of our most vulnerable populations.

Roughly 60% of the patients treated at 3R are 55 or older. Doctors Pruski and Nash use a combination of non-invasive modalities approved by the FDA, including physical therapy, chiropractic care, regenerative medicine and biological therapy to help aging patients relieve pain and inflammation, speed recovery of injured or damaged areas, and improve their quality of life.

Dr. Pruski said while treatments vary for each individual patient, the doctors at 3R are seeing very successful outcomes treating aging patients suffering from chronic pain with the use of advanced technologies and interventions such as Regenerative Injection Therapies, Pulsed Electromagnetic Field (PEMF) therapies and Hako-Med therapy, which stimulates the nerves to provide muscle re-education and pain relief for a variety of degenerative joint conditions and nerve problems, along with muscle work, massage therapy and home exercise.

Our entire focus is preventative and regenerative care so that patients of all ages and all activity levels can maintain a healthy, pain-free life, said Dr. Pruski. We see everyone from professional and retired pro athletes, to everyday people who just want to be able to pick up their grandkids or make themselves a cup of coffee without pain. Todays technology allows us to accomplish healing and pain management goals for all of our patients in the most pain-free, non-invasive way possible. Most treatments last less than 30 minutes, require nothing more than a Band-Aid, with no recovery or down time, and you can drive yourself home.

Most insurance companies cover the majority of treatments at 3R Regenerative Repair & Relief, however coverage for biologic injection procedures may vary from policy to policy.

For more information on services and telemedicine consultations at 3R please visit https://www.3RRegenerativeMedicine.com.

See the original post:
Regenerative Therapies Helping Houston Seniors Find Non-Surgical Relief from Chronic Pain, Arthritis at Woodlands Clinic - Woodlands Online

(WZAW) -- Scientists around the world are racing to understand COVID-19 and the novel coronavirus that causes the disease. Among the questions theyre asking is why do most people who are infected show mild to moderate symptoms, or possibly no symptoms at all, whereas others develop a severe form of the disease.

To help gather more insights, DNA company 23andMe has launched a research study to help determine whether genetics may play a role. 23andMes unique research model, with millions of customers consenting to participate, offers their scientists a powerful tool for potential insight into the role genetics may play in explaining differences in the severity of the novel coronavirus.

With more than 400,000 existing 23andMe customers already enrolled to participate, including several thousand whove confirmed they had the virus, 23andMe is opened enrollment to people who have been hospitalized with the disease but are not currently customers. Opening up the research to individuals with more severe symptoms will increase their ability to learn how genes may play a role in the severity of this disease.

Joyce Tung, vice president of research at 23andMe joined NewsChannel 7 at 4 on Tuesday to talk about how the research is helping to understand the role genetics plays in the severity of COVID-19 symptoms.

Based on our past studies on infectious diseases, for some of those we saw that genes for example that are part of the immune system influence the susceptibility too in severity of those diseases, Tung explained.

Tung said researchers hope genetics can give us insights into the biological pathways in humans that influence the severity of the disease.

And perhaps with this information, we can develop different treatments, she added.

Continued here:
Researchers look at the role genetics play in the severity of coronavirus symptoms - WSAW

Cancer metastasis is a major cause of death which has attracted intense scientific research over the years. Metastasis is the process where cancer propagates to other tissues from where it started initially. It has long been thought that the genetic mutations which occur in the cells that cause cancer in them can also provide these cells with the ability to pervade other tissues further. But a question remainsdoes the inherited genetic make up of a person have a role in metastasis?

Before proceeding further, let us quickly recapitulate some facts. In most cancers, the genetic mutation occurs in somatic cells. This means that these cancer-causing genetic mutations are not inherited. For a genetic mutation to be called inherited, the mutations must have occurred in the germ cells, that is the cells involved in reproduction. Precisely, the egg cells and the semen.

The somatic mutations occur in a lifetime mostly due to external factors, like life style habits or environmental factors.

Apart from the somatic mutations, what the inherited mutations do in cancer metastasis has been a profound question in cancer research. Now, a Nature Medicinepublication has come out with some elaborated data which indicate the link between cancer metastasis and someones inherited genetics.

This study is based on melanoma, a type of cancer of the skin and finds that a single gene can alter the level of metastasis in this kind of cancer. The researchers also think that this gene and others can have similar effects in other cancer types.

The specific gene in question is the APOE gene, which is present in all types of cells of the body. The production of the gene, a particular protein, appears to have interference in a number of processes that cancer cells undertake to metastasise. The important processes are like forming blood vessels, penetrating deep into other healthy tissues as well as resisting attacks of bodys cancer targeting immune cells.

The APOE gene has three types, namely, ApoE2, ApoE3, ApoE4. An individual carries one type of the APOE gene among its varieties. It has been found that different melanoma patients have different degrees of progression of the cancer. The probable answer to it could be the presence of different APOE genes in different people.

In the latest study, experiments with mice show that those possessing the ApoE4 variety of the gene have the smallest tumour and also the least spread of melanoma. Also, it was found that ApoE4 is the most effective version of the gene that could provide enhanced immune response to tumour cells. In comparison with other types of the APOE gene, mice having the ApoE4 type have higher amount of T cells involved in fighting melanoma tumour along with reduced blood vessels. Benjamin Ostendorf, the first author of the study says, We think that a major impact of the variations in ApoE arises from differences in how they modulate the immune system's attack.

Recruiting genetic data from more than 300 melanoma patients also showed similar results as in the mice. Patients possessing the ApoE4 type could survive the longest and patients with ApoE2 type survived the least. While, the ApoE3 types ability to suppress tumour progression lies in between the other two.

The genetic inheritance and its link to cancer progression is hoped to better development of cancer therapeutics in future.

View post:
How Spread of Cancer Is Related to Genetics - NewsClick

People with a genetic mutation that increases the risk of dementia also have a greater chance of having severe Covid-19, researchers have revealed.

The study is the latest to suggest genetics may play a role in why some people are more vulnerable to the coronavirus than others, and could help explain why people with dementia have been hard hit: dementia is one of the most common underlying health conditions among those who have died from Covid-19 in England and Wales.

It is not just age: this is an example of a specific gene variant causing vulnerability in some people, said David Melzer, a professor of epidemiology and public health at Exeter University and a co-author of the study.

Writing in the Journal of Gerontology: Medical Sciences, Melzer and colleagues report how they analysed data from the UK Biobank, a research endeavour that has collected genetic and health data on 500,000 volunteers aged between 48 and 86.

The team focused on a gene called ApoE this gives rise to proteins involved in carrying fats around the body, and can exist in several forms. One such variant, called e4, is known to affect cholesterol levels and processes involved in inflammation, as well as increasing the risk of heart disease and dementia.

The researchers found 9,022 of almost 383,000 Biobank participants of European ancestry studied had two copies of the e4 variant, while more than 223,000 had two copies of a variant called e3. The former, the team add, have a risk of dementia up to 14-fold higher than the latter.

The team then looked at positive tests for Covid-19 between 16 March and 26 April when testing for the coronavirus was largely carried out in hospitals, suggesting the cases were severe.

The results reveal 37 people who tested positive for Covid-19 had two copies of the e4 variant of ApoE, while 401 had two copies of the e3 variant. After taking into account various factors, including age and sex, the team say people with two e4 variants had more than double the risk of severe Covid-19 than those with two e3 variants.

Melzer said the findings were not down to people with two e4 variants being more likely to be living in a care home settings that have been hard hit by Covid-19 since the association remained even when the team excluded participants with a diagnosis of dementia. None of the Covid-19 positive participants with two e4 variants of the ApoE gene had a dementia diagnosis.

It is pretty bulletproof whatever associated disease we remove, the association is still there. So it looks as if it is the gene variant that is doing it This association is not driven by people who actually have dementia, said Melzer.

The team say further work is needed to unpick the link.

Prof Tara Spires-Jones, an expert in neurodegeneration at the University of Edinburgh who was not involved in the study, said the large number of Biobank participants meant the association between the ApoE genetic variants and Covid-19 risk was robust, but stressed the study did not prove the former caused the latter. Nevertheless, she said, the study was important.

It is possible that the role of ApoE in the immune system is important in the disease and future research may be able to harness this to develop effective treatments, she said.

Fiona Carragher, a director of research and influencing at Alzheimers Society, said people with dementia and their families were desperately worried, adding the government must take urgent action to protect people with dementia. But, she said, more research was needed to delve into the possible link between the e4 variant of ApoE and severe Covid-19.

Other factors may contribute, so it is difficult to draw firm conclusions at this stage. But clearly much more in-depth research is urgently needed to fully understand why people with dementia seem to be at a higher risk and to what extent factors like ethnicity and genetics might play a role, she said.

But Prof David Curtis, honorary professor at the UCL Genetics Institute, urged caution. He noted that among the studys limitations, diagnoses of dementia in recent years are unlikely to be captured, meaning that the link between the e4 variant and severe Covid-19 may still be driven by more people with two e4 variants having dementia than those with two e3 variants.

Im afraid this study does not really convince me that the ApoE e4 allele [gene variant] is really an independent risk factor for severe Covid-19 infection, he said. I would want to see this tested in a sample where dementia could be more confidently excluded, perhaps a younger cohort. I am sure additional data will soon emerge to illuminate this issue.

Go here to read the rest:
Research reveals gene role in both dementia and severe Covid-19 - The Guardian

Saeed Khoshnood,1,2 Mohammad Savari,1,2 Effat Abbasi Montazeri,1,2 Ahmad Farajzadeh Sheikh1,2

1Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Correspondence: Ahmad Farajzadeh SheikhInfectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan 61357-15794, IranTel +98 9161133491Fax +98 61 3333 2036Email farajzadehah@gmail.com

Introduction: Acinetobacter baumannii is an opportunistic pathogen responsible for nosocomial infections. The emergence of colistin-resistant A. baumannii is a significant threat to public health. The aim of this study was to investigate the molecular characterization and genotyping of clinical A. baumannii isolates in Southwestern Iran.Methods: A total of 70 A. baumannii isolates were collected from patients admitted to Imam Khomeini Hospital in Ahvaz, Southwestern Iran. Minimum inhibitory concentration test was conducted by using Vitek 2 system. The presence of biofilm-forming genes and colistin resistance-related genes were evaluated by PCR. The isolates were also examined for their biofilm formation ability and the expression of pmrA and pmrB genes. Finally, multilocus sequence typing (MLST) and PCR-based sequence group were used to determine the genetic relationships of the isolates.Results: Overall, 61 (87.1%) and 9 (12.8%) isolates were multidrug-resistant (MDR) and extensively drug-resistant (XDR), respectively. Colistin and tigecycline with 2 (2.8%) and 32 (45.7%) resistance rates had the highest effect. Among all the isolates, 55 (78.5%), 7 (10%), and 3 (4.3%) were strong, moderate, and weak biofilm producers, respectively. The frequency rates of biofilm-related genes were 64 (91.4%), 70 (100%), 56 (80%), and 22 (31.42%) for bap, ompA, csuE, and blaPER1, respectively. Overexpression of pmrA and pmrB genes was observed in two colistin-resistance isolates, but the expression of these genes did not change in colistin-sensitive isolates. Additionally, 37 (52.8%) and 8 (11.4%) isolates belonged to groups 1 (ICII) and 2 (IC I), respectively. MLST analysis revealed a total of nine different sequence types that six isolates belonged to clonal complex 92 (corresponding to ST801, ST118, ST138, ST 421, and ST735). Other isolates were belonging to ST133 and ST216, and two colistin-resistant (Ab4 and Ab41) isolates were belonging to ST387 and ST1812.Conclusion: The present study revealed the presence of MDR and XDR A. baumannii isolates harboring biofilm genes and emergence of colistin-resistant isolates in Southwestern Iran. These isolates had high diversity, which was affirmed by typing techniques. The control measures and regular surveillance are urgently needed to preclude the spread of these isolates.

Keywords: Acinetobacter baumannii, drug resistance, colistin, MLST, clonal complex

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
Survey on Genetic Diversity, Biofilm Formation, and Detection of Colis | IDR - Dove Medical Press

A Snohomish County man who was the countrys first confirmed COVID-19 patient was probably not the source of the coronavirus outbreak in Washington state, according to a new genetic analysis by an international group of scientists.

The finding upends one of the most compelling scientific narratives of the pandemics arrival in the United States, but it also showcases the power of quick public-health action, said Michael Worobey, lead author of the report and head of the University of Arizonas Department of Ecology and Evolutionary Biology.

As researchers learn more about the pandemics roots, its becoming clear that the virus entered the United States via multiple paths and at multiple times. But Washington still seems to be the place where it first took hold in this country and flared into a community outbreak, said co-author Joel Wertheim, a molecular epidemiologist at the University of California, San Diego.

The Snohomish County man, sometimes erroneously referred to as patient zero, started feeling sick after he returned Jan. 15 from a visit to Wuhan, China the pandemics birthplace. He was confirmed positive Jan. 20. Public-health officials tested and isolated everyone they could identify who came into contact with him, and found no other infections.

So it was baffling when a second case emerged Feb. 28 and genetic analysis showed it was similar to the first, differing by only two mutations. Trevor Bedford, a computational biologist at the Fred Hutchinson Cancer Research Center, and his colleagues, concluded that the two cases were linked with the Snohomish County man as the original source. They also estimated the virus had been spreading silently for six weeks.

But the new analysis, which was posted Monday on the preprint site bioRxiv and has not been peer-reviewed, says its more likely that quick action by public-health officials succeeded in stamping out any spread from the first infection, turning it into a dead end. The outbreak that eventually flared in late February and early March was probably the result of a separate introduction from China around Feb. 13, either directly or by way of British Columbia, Worobey and his colleagues argue.

To reach that conclusion, the team examined many more viral genomes than had been available earlier in the outbreak and found none in Washington that exactly matched the earliest known infection. They also found none of the expected missing link genomes, intermediate between the first case and subsequent infections.

They then used computer simulations to, as Worobey put it, rerun the tape of evolution over and over again. Thousands of times, in fact, to see how the viral genomes would be expected to change and evolve. Again, they found no indication that the viral strain carried by the Snohomish County man was the source of the states spreading outbreak.

To understand how a closely related strain might have been introduced separately, the team examined travel patterns and found that the Feb. 2 ban on air travel from China was actually quite leaky, with an estimated 40,000 U.S. residents returning to the United States from China via airports including Seattle-Tacoma International Airport.

The remaining influx likely provided ample opportunity for a second introduction to Washington State, the report says. It is also possible that the virus entered via nearby Vancouver, British Columbia, which is closely linked to both China and Washington state.

But Dr. Jared Roach, a senior research scientist at the Institute for Systems Biology in Seattle, said the new analysis is not likely to be the final word. Among other things, the model the researchers used for their simulations didnt appear to account for super-spreader events, like a choir practice where many people were infected, which could affect the virus evolutionary path, he said. Nor did it account for other possible variations in the way the virus spread, with some lineages fizzling out and others catching fire.

They are far too confident their answer is the only answer, Roach said. I think there are other explanations they didnt consider.

In a series of 18 tweets Monday, Bedford said he now agrees a second introduction was probably responsible for Washingtons outbreak. However, hes still convinced that second seed was planted fairly early, sometime between Jan. 18 and Feb. 9.

The exact timing is difficult to determine, Worobey said. But the implications are important.

If the virus had a six-week head start, spreading unseen and, thus, untouchable by public-health measures, then it was essentially hopeless theres not much anyone could have done to prevent the eventual flare-up.

But if, as the new analysis suggests, the virus didnt take hold until mid-February, then control might have been possible if the country hadnt fumbled the rollout of testing and tracing capacity.

The timing suggests strongly that those weeks that were lost were pretty consequential weeks, and that we did have more of a chance (of stopping it) than we realized, Worobey said.

The paper also criticized the U.S. Food & Drug Administration for halting the Seattle Flu Study, which could have provided valuable insights into the early spread of the virus. The project, funded by Bill Gates, had been collecting nasal swabs from volunteers across King County to study the spread of respiratory disease. Their samples represented a potential wealth of information, but researchers were initially barred from accessing that information because the project lacked specific approval to test the samples for the coronavirus.

The timeline of the pandemics spread is being revealed in bits and pieces, and a full picture probably wont emerge for quite some time. At least two Washington residents who were sick in December later tested positive for antibodies to the new coronavirus, though its not clear when their infections occurred. The first recorded death in the United States occurred in Snohomish County on Feb. 26, but posthumous analyses in California confirmed two earlier fatalities, the first on Feb. 6.

Read more:
New analysis may rewrite the history of Washington states coronavirus outbreak - Seattle Times

Dementia is one of the most common underlying health conditions in people who have died from the novel coronavirus in England and Walesnow British researchers say they might know why. A study has found that people with a specific genetic mutation known to increase the risk of dementia also have a much greater chance of having severe COVID-19, according to The Guardian. Its the latest study to suggest genetics may play a role in why some people are hit harder by the coronavirus than others, and could help explain why people with dementia appear to be particularly vulnerable. It is not just age: This is an example of a specific gene variant causing vulnerability in some people, said study co-author David Melzer, a professor of epidemiology and public health at Exeter University. The team found that having the gene that raises the risk of dementia could make people twice as likely to suffer badly from the virus.

Read the original:
Genetic Mutation Appears to Link COVID-19 to Dementia, Study Finds - The Daily Beast

Israeli scientists at the Israel Institute for Biological Research (IIBR) have found that a combination of two existing antiviral drugs for Gauchers disease appears to inhibit the growth of SARS CoV-2, the virus that leads to COVID-19 and may work against other virus infections, including a common flu strain.

The IIBR is a governmental research center specializing in biology, chemistry and environmental sciences that falls under the jurisdiction of the Prime Ministers Office. During the pandemic, announcements have been issued by the Defense Ministry.

According to a press announcement on Tuesday, scientists at the secretive bio-defense lab tested an analog of the FDA-approved drug Cerdelga, and an analog of a second drug, Venglustat, currently in advanced trials. They found that, in combination, the drugs led to a significant reduction in the replication capacity of the coronavirus and to the destruction of the infected cells.

The two drugs are used to treat Gaucher disease, an inherited genetic condition most common in people of Ashkenazi Jewish descent that leads to the buildup of fatty substances in certain organs, particularly the spleen and liver, and can affect their function. The disease can also lead to skeletal abnormalities and blood disorders, In rare cases, Gauchers disease can also lead to brain inflammation, according to the Mayo Clinic. The disease is unrelated to COVID-19.

The Israeli researchers tested the drugs on mouse models using four different RNA viruses: Neuroinvasive Sindbis virus (SVNI), an infection transmitted via mosquitos that can lead to years of debilitating musculoskeletal symptoms; West Nile virus (WNV), also a mosquito-borne disease that can cause neurological disease and is potentially fatal; Influenza A virus, a strain of the flu; and SARS-CoV-2.

The researchers found that the two drugs were effective in all four cases. They work by inhibiting glucosylceramide synthase *GCS), an enzyme involved in the production of glucocerebroside, a lipid that accumulates in the tissues of patients affected with Gaucher disease. In the lab setting, they inhibited the replication of the viruses, and in the case of mice infected with SVNI, increased their survival rate.

In the case of COVID-19, the drugs have an antiviral effect on the SARS-CoV-2 clinical isolate in vitro, with a single dose able to significantly inhibit viral replication within 2448 h.

The two drugs are currently being tested for their effectiveness in treating animals infected with the coronavirus.

The study, published in bioRxiv, has not yet been peer-reviewed. The authors are all from the IIBRs Department of Infectious Diseases

The data suggests that GCS inhibitors can potentially serve as a broad-spectrum antiviral therapy and should be further examined in preclinical and clinical trial, the scientists wrote, adding that repurposing approved drugs can lead to significantly reduced timelines and required investment in making treatment available.

Treatment of a new disease such as COVID-19 using an existing, approved drug may serve as an effective short-term solution considering that one of the major challenges in addressing such a pandemic is the length of time it takes for both the research and approval phases of new drugs, the Defense Ministry wrote in the announcement.

The lab has been conducting various research into COVID-19 for several months, including studies on possible treatment and a vaccine. Israeli Prime Minister Benjamin Netanyahu tapped the institute in early February to begin development on inoculation. In early April, the center reported significant progressand trials on animals.

The institute has also been involved in plasma collection from Israelis who have recovered from COVID-19 to research antibodies, proteins made by the immune system that can attack the virus.

Earlier this month, the IIBR said it completed a groundbreaking scientific development toward a potential treatment based on an antibody that neutralizes SARS-CoV2. The development had three key parameters, according to the IIBR: first, the antibody is monoclonal (lab-made identical immune cells that are all clones of a unique parent cell), and contains a low proportion of harmful proteins; second, the institute has demonstrated the ability of the antibody to neutralize the coronavirus; and third, the antibody was specifically tested on SARS CoV-2.

The Ness Ziona-based institute said it is now pursuing a patent for its development after which it will approach international manufacturers.

A number of Israeli scientific teams and over 100 groups worldwide are currently working to develop a vaccine or a treatment for COVID-19.

At least 10 candidate vaccines are in clinical evaluation, including those of Massachusetts-based company Moderna which was the first to develop an experimental vaccine that went into trial quickly, and California-based biotech firm Gilead Sciences, which is evaluating the safety and efficacy of its novel antiviral drug Remdesivir, developed originally for Ebola, in adults diagnosed with COVID-19.

Last month, Israeli scientists at theMigal Galilee Research Institute formed a new company, MigVax, to further adapt a vaccine they developed for a deadly coronavirus affecting poultry for human use. The scientists had been working for four years to develop a vaccine for IBV (Infectious Bronchitis Virus) which affects the respiratory tract, gut, kidney and reproductive systems of domestic fowl.

Also in April, an Israeli scientist wasawarded a US patent for his innovative vaccine design for the corona family of viruses and indicated that he was on track to develop a vaccine for SARS CoV2.

Meanwhile, two Israeli bio-medical companies nabbed FDA approval for separate trials in the US with their respective solutions for COVID-19 as part of a compassionate use program, a treatment option that allows for the use of not-yet-authorized medicine for severely ill patients.

BothRedHill BioPharma, a publicly-traded specialty biopharmaceutical company, andPluristem Therapeutics, also a public company that specializes in placental cell therapy, were given the green light for their imminent separate studies with the investigational drug, opaganib, and the placental cell therapy PLX, respectively.

Continued here:
Israeli Lab: Drugs For Gaucher Disease May Work Against Coronavirus, Other Viral Infections | Health News - NoCamels - Israeli Innovation News

Market Expertz has very recently published a report on the Stem Cell Banking market, which delves deeper into a bunch of insightful as well as comprehensive information about the Stem Cell Banking industrys ecosystem. The research report on the Stem Cell Banking market covers both qualitative as well as quantitative details that focus entirely on the various parameters such as Stem Cell Banking market risk factors, challenges, industrial developments, new opportunities available in the Stem Cell Banking report. These factors are the ones that determine the functioning and trends in the forecasted period for the market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

Avail your copy of the sample of the report on the global Stem Cell Banking [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/122606

With the growing number of new players entering the Stem Cell Banking market, expansion in businesses is also improving. Then Stem Cell Banking report focuses on boosting a series of parameters such as revenue shares, optimizing cost structure, offering better services, Stem Cell Banking market demand or supply chain, development policies, which mainly maps to streamline business processes during the projected timeline.

The fundamental drivers, as well as restraints, are identified by the recent trends and historical milestones gathered by the Stem Cell Banking market. It also demonstrates the brief evaluation of the investments, Stem Cell Banking production, innovative technologies, and growth rate of the specific businesses.

Leading Stem Cell Banking manufacturers/companies operating at both regional and global levels:

Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/122606

The creative advancements are investigated widely to understand the probable impact on the growth of the global Stem Cell Banking market.

The Stem Cell Banking market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The readers can assess detailed and strategical information about each segment. The Stem Cell Banking market report also includes a blend of statistics about sales, consumption rate, volume, value, gross margin, and more.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Banking sector and can help companies in deciphering the optimum business move to reach their desired business goals.

product landscape:

Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells , (HESCS), Dental Pulp-Derived Stem Cells (DPSCS)

Application landscape:

Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation

End user landscape:

Personalized Banking Applications, Research, Clinical Application

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

To get in-depth insights into the global Stem Cell Banking market, reach out to us @ https://www.marketexpertz.com/customization-form/122606

Thus, with the rising adoption of the Stem Cell Banking market in the international sector, the industry for the global Stem Cell Banking market is expected to represent a predicted outlook during the forecast phase from 2020-2027. Additionally, the report on the Stem Cell Banking market delivers a systematic representation of the growth opportunities, Stem Cell Banking market dynamics, and the existing trends are anticipated to shape the growth of the Stem Cell Banking market across the globe.

Geographically, this report studies the top producers and consumers in these key regions:

North America

Europe

China

Japan

Southeast Asia

India

A conscious effort is made by the subject matter experts to analyze how some business owners succeed in maintaining a competitive edge while the others fail to do so makes the research interesting. A quick review of the realistic competitors makes the overall study a lot more interesting. Opportunities that are helping product owners size up their business further add value to the overall study.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/122606

The Stem Cell Banking Market Research/Analysis Report addresses the following questions:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/2020-stem-cell-banking-global-market

To summarize, the global Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

Read the original here:
Impact of Covid-19 on Stem Cell Banking Market 2020: Remarking Enormous Growth with Recent Trends | Cord Blood Registry (CBR) Systems (US), Cordlife...

Scientists in the Department of Biomedical Engineering at Texas A&M University are seeking to advance the field of 3D bioprinting functional tissues, by conducting research into the development of new biomaterials.

Dr. Akhilesh K. Gaharwar, an associate professor in the department, has created a highly 3D printable bioink, which can be used as a platform for generating anatomical-scale functional tissues. The new material developed by Gaharwars research group, known as Nanoengineered IonicCovalent Entanglement (NICE) bioink, has been designed to overcome the deficiencies of current bioinks in relation to structural stability. Commenting on the benefits of the NICE bioink, Gaharwar states: The next milestone in 3D bioprinting is the maturation of bioprinted constructs toward the generation of functional tissues.

Our study demonstrates that NICE bioink developed in our lab can be used to engineer 3D-functional bone tissues.

Bioprinting bone tissue

In their study, Gaharwars research group first outlined the emergence of 3D bioprinting as a technique for fabricating patient-specific, implantable constructs for regenerative medicine. Using hydrogels and combining them with cells and growth factors, these bioinks are 3D printed to create tissue-like structures intended to imitate the function of natural tissues.

One particularly useful application of the technology is in patient-specific bone grafting, a surgical procedure that replaces missing bone in order to repair bone fractures. As traditional treatments for managing bone defects and injuries are slow and expensive, Gaharwar states that developing replacement bone tissues with bioprinting could create exciting new treatments for patients. These can be used to treat defects and conditions such as arthritis, bone fractures, dental infections and craniofacial defects.

Recent advancements in the field have come from Rice University and the University of Maryland (UMD). Scientists at these institutions have outlined a new proof-of-concept for 3D printing artificial bone tissue to help repair damage related to arthritis and sporting accidents.

In late 2019 onboard the ISS, 3D Bioprinting Solutions, a Russian bio-technical research laboratory, 3D bioprinted bone tissue in zero gravity. Leveraging its Organ.Aut 3D bioprinter, the labs researchers hope to one day create real bone implants for astronaut transplantation on long interplanetary missions.

Nanoengineered bioinks for stronger bone structures

In the bioprinting process, cell-laden biomaterials flow through a nozzle in liquid form, however immediately solidify as soon as theyre deposited. It is necessary for bioinks to act as cell carriers and structural components, which requires them to be highly printable while providing a robust and cellfriendly microenvironment.

As outlined in the research paper, Gaharwars team explain that current bioinks in use lack the sufficient biocompatibility, printability, structural stability and tissuespecific functions needed for preclinical and clinical applications of bioprinting. The potential applications of bioprinting have been limited due to the lack of bioinks capable of meeting the demands of both 3D printing and tissue engineering. For example, ideal bioinks must be capable of extruding into stable 3D structures, while also protecting cells during and after printing, and providing an appropriate environment that can be remodeled into the target tissue. Unfortunately, conventional hydrogels are weak and poorly printable, explain the authors.

In response to this issue, Gaharwars research group has developed the NICE bioink formulation specifically for 3D bone bioprinting. NICE bioinks are a combination of two reinforcement techniques (nonreinforcement and ionic-covalent network). Used together, they provide an effective reinforcement that results in much stronger bone structures. Explaining the benefits of the material, the researchers write: The NICE bioinks allow precise control over printability, mechanical properties and degradation characteristics, enabling custom 3D fabrication of mechanically resilient, cellularized structures.

Once the bioprinting process is complete, the cell-laden NICE networks are crosslinked to form stronger scaffolds. Using this technique, Gaharwar and his team have been able to produce full-scale, cell-friendly reconstructions of human body parts, including ears, blood vessels, cartilage and bone segments.

In their tests, the researchers found that the enclosed cells began depositing new proteins containing a cartilage-like extracellular matrix that subsequently calcifies to create a mineralized bone over a three-month period. Five percent of these 3D bioprinted scaffolds consisted of calcium, which is similar to cancellous bone, the network of spongy tissue typically found in vertebral bones.

Gaharwars research group used a genomics technique called whole transcriptome sequencing (RNA-seq) to examine how these bioprinted structures were able to induce stem cell differentiation. RNA-seq works by capturing a snapshot of all genetic communication inside the cell at a given moment. The team worked with Dr. Irtisha Singh, assistant professor at the Texas A&M Health Science Center, who served as a co-investigator.

Using their bioink and research results, Gaharwars team plans to demonstrate in vivo functionality of the 3D bioprinted bone tissue.

The study, Nanoengineered Osteoinductive Bioink for 3D Bioprinting Bone Tissue is published in ACS Applied Materials & Interfaces. It is written by David Chimene, Logan Miller, Lauren M. Cross, Manish K. Jaiswal, Irtisha Singh, and Akhilesh K. Gaharwar.

The nominations for the 2020 3D Printing Industry Awards are now open. Who do you think should make the shortlists for this years show? Have your say now.

Subscribe to the 3D Printing Industry newsletter for the latest news in additive manufacturing. You can also stay connected by following us on Twitter and liking us on Facebook.

Looking for a career in additive manufacturing? Visit 3D Printing Jobs for a selection of roles in the industry.

Featured image shows Dr. Akhilesh Gaharwar. Photo via Texas A&M Engineering.

Here is the original post:
Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry